These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 26106232)

  • 1. Response to Comment on Thomsen et al. Incretin-Based Therapy and Risk of Acute Pancreatitis: A Nationwide Population-Based Case-Control Study. Diabetes Care 2015;38:1089-1098.
    Thomsen RW; Pedersen L; Møller N; Kahlert J; Beck-Nielsen H; Sørensen HT
    Diabetes Care; 2015 Jul; 38(7):e108-9. PubMed ID: 26106232
    [No Abstract]   [Full Text] [Related]  

  • 2. Comment on Thomsen et al. Incretin-Based Therapy and Risk of Acute Pancreatitis: A Nationwide Population-Based Case-Control Study. Diabetes Care 2015;38:1089-1098.
    Smits MM; Muskiet MH; Tonneijck L; van Raalte DH
    Diabetes Care; 2015 Jul; 38(7):e106-7. PubMed ID: 26106231
    [No Abstract]   [Full Text] [Related]  

  • 3. ACP Journal Club. Incretin use was not associated with increased risk for acute pancreatitis.
    Schectman J
    Ann Intern Med; 2015 Jun; 162(12):JC12. PubMed ID: 26075777
    [No Abstract]   [Full Text] [Related]  

  • 4. Incretin-based therapy and risk of acute pancreatitis: a nationwide population-based case-control study.
    Thomsen RW; Pedersen L; Møller N; Kahlert J; Beck-Nielsen H; Sørensen HT
    Diabetes Care; 2015 Jun; 38(6):1089-98. PubMed ID: 25633664
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The safety of incretin based drugs.
    Montori VM
    BMJ; 2014 Apr; 348():g2779. PubMed ID: 24764568
    [No Abstract]   [Full Text] [Related]  

  • 6. Q: Do incretin drugs for type 2 diabetes increase the risk of acute pancreatitis?
    Olansky L
    Cleve Clin J Med; 2010 Aug; 77(8):503-5. PubMed ID: 20682512
    [No Abstract]   [Full Text] [Related]  

  • 7. Incretin-based therapies are associated with acute pancreatitis: Meta-analysis of large randomized controlled trials.
    Roshanov PS; Dennis BB
    Diabetes Res Clin Pract; 2015 Dec; 110(3):e13-7. PubMed ID: 26643128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes.
    Zhang Z; Chen X; Lu P; Zhang J; Xu Y; He W; Li M; Zhang S; Jia J; Shao S; Xie J; Yang Y; Yu X
    Cardiovasc Diabetol; 2017 Mar; 16(1):31. PubMed ID: 28249585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association Between Incretin-Based Drugs and the Risk of Acute Pancreatitis.
    Azoulay L; Filion KB; Platt RW; Dahl M; Dormuth CR; Clemens KK; Durand M; Hu N; Juurlink DN; Paterson JM; Targownik LE; Turin TC; Ernst P; ; Suissa S; Dormuth CR; Hemmelgarn BR; Teare GF; Caetano P; Chateau D; Henry DA; Paterson JM; LeLorier J; Levy AR; Ernst P; Platt RW; Sketris IS
    JAMA Intern Med; 2016 Oct; 176(10):1464-1473. PubMed ID: 27479930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incretin based drugs and risk of acute pancreatitis in patients with type 2 diabetes: cohort study.
    Faillie JL; Azoulay L; Patenaude V; Hillaire-Buys D; Suissa S
    BMJ; 2014 Apr; 348():g2780. PubMed ID: 24764569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preying on the pancreas? Scientists debate whether newer diabetes medications do harm.
    Berg EG
    Diabetes Forecast; 2013 Oct; 66(10):26, 28, 30-1. PubMed ID: 24224353
    [No Abstract]   [Full Text] [Related]  

  • 12. Incretin-based drugs and adverse pancreatic events: almost a decade later and uncertainty remains.
    Azoulay L
    Diabetes Care; 2015 Jun; 38(6):951-3. PubMed ID: 25998285
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incretin-based glucose-lowering medications and the risk of acute pancreatitis and/or pancreatic cancer: Reassuring data from cardio-vascular outcome trials.
    Nauck MA; Meier JJ; Schmidt WE
    Diabetes Obes Metab; 2017 Sep; 19(9):1327-1328. PubMed ID: 28432752
    [No Abstract]   [Full Text] [Related]  

  • 14. Using real-world data to evaluate the association of incretin-based therapies with risk of acute pancreatitis: a meta-analysis of 1,324,515 patients from observational studies.
    Wang T; Wang F; Gou Z; Tang H; Li C; Shi L; Zhai S
    Diabetes Obes Metab; 2015 Jan; 17(1):32-41. PubMed ID: 25200423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The safety of incretin based drug treatments for type 2 diabetes.
    Bolen SD; Maruthur NM
    BMJ; 2016 Feb; 352():i801. PubMed ID: 26888024
    [No Abstract]   [Full Text] [Related]  

  • 16. Incretin-based pharmacotherapy and risk of adverse pancreatic events in the ethnic Chinese with diabetes mellitus: A population-based study in Taiwan.
    Tseng CM; Liao WC; Chang CY; Lee CT; Tseng CH; Hsu YC; Lin JT
    Pancreatology; 2017; 17(1):76-82. PubMed ID: 27743712
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of Pancreatitis With Incretin Therapies Versus Thiazolidinediones in the Veterans Health Administration.
    Wilhite K; Reid JM; Lane M
    Ann Pharmacother; 2024 Jul; 58(7):685-689. PubMed ID: 37881914
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors.
    Boland CL; Degeeter M; Nuzum DS; Tzefos M
    Ann Pharmacother; 2013 Apr; 47(4):490-505. PubMed ID: 23548652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incretin-based therapies: facing the realities of benefits versus side effects.
    Lebovitz HE
    Diabetes Technol Ther; 2013 Nov; 15(11):909-13. PubMed ID: 24111860
    [No Abstract]   [Full Text] [Related]  

  • 20. Are incretin mimetics and enhancers linked to pancreatitis and malignant transformations in pancreas?
    de Heer J; Göke B
    Expert Opin Drug Saf; 2014 Nov; 13(11):1469-81. PubMed ID: 25270593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.